OssDsign: While adding potential, acquisition prompts questions on financing
Redeye raises its long-term estimates and valuation somewhat following OssDsign’s broadening towards synthetic bone grafts for spinal fusion through the acquisition of Sirakoss. We have a relatively conservative stance on the new product’s sales potential at present, though increased clinical validation and demonstrated commercial interest could prompt a reassessment further out.